Background

Central Nervous System Therapeutics Market was valued at USD 84.24 Billion in 2020 and is projected to reach USD 168.43 Billion by 2028, growing at a CAGR of 9.05% from 2021 to 2028.

Current drug treatments for neurodegenerative diseases like Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease, and traumatic brain injury (TBI) are lacking effectiveness. Clinical trials targeting amyloid levels in AD patients have not shown improvement in memory and have led to toxicity issues. A new approach suggests targeting abnormal calcium signaling cascades, which are linked to various aspects of neurodegenerative diseases. This strategy aims to normalize sustained calcium imbalance, a key factor associated with amyloid pathology, tau hyperphosphorylation, synaptic dysfunction, and memory deficits.

Calcium signaling